Globrands Group: What Is Really at Stake in the JTI Renewal
The main article argued that 2027 is already in the room. This follow-up shows why: even if the JTI agreement is renewed, the company already warns that the profit rate will fall from 2027, and the current contract shows that bargaining power still sits first with the brand owner.
What the Main Article Already Established, and What This Follow-Up Is Isolating
The main article argued that Globrands ended 2025 with better cash flow, but without resolving its core dependence on JTI and BAT. This follow-up isolates the JTI thread because that is where the gap sits between the risk everyone sees and the risk that is easier to miss. The visible risk is non-renewal. The more interesting and less obvious risk is that the company now says explicitly that even if a new agreement is signed, the annual profit rate on JTI products is expected to decline from 2027 versus 2024 and 2025.
That changes the discussion from a simple renewal question into a question about the economics of renewal. In other words, the threat is not only a tail scenario in which JTI walks away. The company itself is flagging a possible base-case outcome in which the relationship stays in place, but the distributor keeps less of the economics.
The second point worth pausing on is where the disclosure appears. It does not sit only in the business-description section. It also appears in the general note and again in the commitments note. That does not read like commercial color. It is a point the company chose to pull into the center of the financial statements.
The Real Risk Is Not Losing the Agreement, but Resetting Its Economics
This is the core issue. The current JTI agreement was extended in February 2020 through February 2027. As part of that update, the ceiling on Globrands’ share of net revenue for 2025 and 2026 was left unchanged from 2024. That means the economics of the next two years are still living inside the old framework. If there is a real shift, it should not come out of 2026 execution itself. It should come out of the renewal point ahead of February 2027.
That is also why operating performance and bargaining economics need to be separated. Even if 2026 turns out to be a decent year in terms of sales, logistics, and collections, that still would not answer the main question. The real question is what will remain for Globrands from this engine once the agreement is rewritten. The company says JTI profitability is expected to decline, but it also says it cannot estimate the size of the decline. So the uncertainty is not only about renewal itself. It is also about the width of the downside range.
This is why a superficial read of “renewal” as a positive headline would be a mistake. Renewal does not necessarily mean preservation. Renewal can also mean moving into weaker economics, and the company is effectively preparing readers for that possibility already.
This chart matters because it sharpens two things at once. On one side, JTI alone represented 46.2% of net sales in 2024 and 45.3% in 2025. On the other side, the fallback the company itself points to in a disruption scenario, expanding the non-tobacco segments, rests on a revenue base of only 20.8% in 2024 and 23.4% in 2025. That is improvement, but it is still not the kind of base that truly offsets JTI’s bargaining power.
Where the Bargaining Power Really Sits
It is easy to read the phrase “exclusive importer and distributor” and assume that Globrands owns the stronger hand because it controls an important local route to market. That reading is incomplete. The current agreement shows that the real scarce asset still sits with the brand owner, while Globrands mainly owns the execution capability inside Israel. That capability matters, but it does not neutralize the power structure.
The first sign is product control. JTI can amend the product list with three months’ notice. The second sign is flow control. Every order is subject to JTI approval, and delayed or partial payment allows JTI to charge interest and suspend or delay future shipments. The third sign is control over the commercial wrapper. All marketing and advertising sit under JTI’s control, supervision, and monitoring, and Globrands committed to provide a dedicated team that works exclusively for JTI and is managed by JTI.
This is where the less obvious insight emerges: Globrands does not earn profit from the marketing activity itself. The company states explicitly that the settlement over marketing costs is handled separately and that it generates no profit from the operating activity tied to marketing, advertising, and the dedicated team. That means the economics of the agreement sit almost entirely in the distribution and commercial spread. If that spread narrows, there is no meaningful service-profit layer on the side to cushion the hit.
It is also important to be precise on pricing. Formally, JTI only “recommends” the product price, while Globrands is supposed to determine the final selling price to customers at its own discretion. In practice, the company says that up to the report date it has sold according to JTI’s recommended price. So on paper there is discretion. Commercially, pricing independence looks much narrower.
Set against that are the balance-sheet demands. Globrands is required to hold average inventory equal to two months of sales, the payment terms to JTI are current + 75, and the company posted a NIS 45 million bank guarantee in JTI’s favor after the contract set a mechanism for reviewing the amount every six months. Put simply, JTI is not just selling brands. It is also dictating how much balance-sheet support needs to stand behind the distribution model.
| Mechanism | What the agreement says | What it means economically |
|---|---|---|
| Economics through 2026 | The ceiling on Globrands’ share of net revenue in 2025 and 2026 stays unchanged from 2024 | 2026 still lives under the old economics, so the real pressure point is the renewal |
| Product control | JTI can revise the product list with 3 months’ notice | The brands remain under supplier control, not distributor control |
| Flow control | Every order requires JTI approval, and delayed payment allows interest and shipment suspension | Bargaining power does not end at signing; it continues through every order cycle |
| Marketing and pricing | Marketing is run by JTI, and the company has in practice followed JTI’s recommended price | The distributor’s real pricing autonomy is narrower than the legal wording suggests |
| Working capital and collateral | Two months of inventory, current + 75 terms, and a NIS 45m bank guarantee | The distributor carries the funding burden and the security layer the supplier demands |
There is also one clause that usually gets too little attention: JTI can require Globrands to establish a separate sales and distribution system for JTI’s exclusive use within 180 days. As of the report date no such request had been made, and the company says it is not aware of any such intention. But the existence of the right matters on its own. It means JTI can pressure the distributor’s cost base without ending the relationship.
The platform is also not freely portable. JTI can terminate immediately in the event of a change of control or a merger, and neither side may assign rights and obligations without prior written consent. So the distribution platform is not a fully transferable asset. Its value remains tied to supplier approval and ownership structure.
What Did Improve in the 2020 Update, and Why That Still Does Not Solve the Problem
To avoid overstating the case, one real layer of protection does need to be acknowledged. In the 2020 update, the parties removed a clause under which JTI could, after notice and after certain uncured breaches, distribute independently in Israel or appoint another distributor instead of Globrands. That is a real improvement inside the life of the agreement because it reduces the immediate threat of replacement during the term.
But that is exactly where the difference lies between protection inside the term and protection at the renewal point. That protection is useful only as long as the current agreement is alive. It says nothing about February 2027. The company now says JTI is negotiating in parallel with other parties interested in distributing its products in Israel. In other words, the mechanism that protects Globrands inside the current term does not change the fact that at renewal JTI regains the full negotiating field.
In that sense, the 2020 update did not change who ultimately owns the relationship. It simply stabilized the period between one signing and the next.
Why the Fallback Is Weaker Than It Looks
In its dependence section, the company says explicitly that it is not only termination with one supplier that could hurt materially, but also a material deterioration in the commercial terms with one of those suppliers. That wording matters because it brings the continuation thesis back to its starting point: Globrands can lose a meaningful part of the economics even without losing JTI altogether.
The company also lays out its toolbox for a termination or non-renewal scenario with one tobacco supplier: expansion with suppliers in other categories, leveraging the existing sales and distribution platform, cost reductions, and deeper activity in sweets, snacks, and lifestyle products. That is a rational response. But it also means the fallback is not supplier-for-supplier substitution. The fallback is mix change, operating adaptation, and time.
That takes us back to the numbers. If the non-tobacco segments represented 23.4% of revenue in 2025, then even solid growth there does not create an overnight counterweight to an engine where JTI alone represents 45.3% of net sales. That is why a weak renewal is not a technical problem that can be solved by a few points of growth in adjacent categories. It is a business-structure question.
What Has to Happen Before February 2027
The first thing that has to happen is more clarity on the economics, not just on whether the agreement exists. A disclosure that merely says “the negotiation continues” will not be enough. What the market needs to understand is whether Globrands can preserve a spread that still justifies the working capital, the guarantee, and the logistics burden the agreement requires.
The second thing is that no new operational demand should emerge that further burdens the distribution layer, for example a separate system or another execution requirement that raises fixed costs before revenue terms even change. Even without losing the agreement, that could erode profit quality.
The third thing is that the non-tobacco segments need to expand not only in volume, but in profit. As long as they remain a relatively small fallback base, JTI stays in the room in every discussion about value, cash generation, and strategic flexibility.
The Bottom Line
What is really at stake in the JTI renewal is not the relationship itself, but the economics of the relationship. The company is already signaling that the more plausible downside is not necessarily separation, but margin erosion from 2027 onward. The current contract shows why that is plausible: JTI controls the brands, the product list, order flow, day-to-day marketing behavior, and a meaningful part of the operating framework, while Globrands carries inventory, funding, and collateral.
The most important point is that renewal on weaker terms can be almost as dangerous as a non-renewal headline, only in a quieter form. Instead of a single event, investors get a business that looks similar from the outside but earns less on every box it moves.
That is exactly why the JTI thread deserves a standalone continuation. Not because it is contractual noise, but because this is where it gets decided whether Globrands remains an efficient distributor with acceptable economics, or an efficient distributor that is simply working harder for a narrower spread.
Disclosure: Deep TASE analyses are general informational, research, and commentary content only. They do not constitute investment advice, investment marketing, a recommendation, or an offer to buy, sell, or hold any security, and are not tailored to any reader's personal circumstances.
The author, site owner, or related parties may hold, buy, sell, or otherwise trade securities or financial instruments related to the companies discussed, before or after publication, without prior notice and without any obligation to update the analysis. Publication of an analysis should not be read as a statement that any position does or does not exist.
The analysis may contain errors, omissions, or information that changes after publication. Readers should review official filings and primary sources before making decisions.